Abstract:Viruses are the smallest infectious agents of animal and plant tissues. Viruses are totally dependent on living cells to survive as they utilize the host cell's own replication processes, in order to reproduce themselves. HIV is the causative agent of AIDS. HIV is an unusually difficult to treat because it incorporate its own genetic material into the genome of an infected host cell. It infects T cells that carry the CD4 antigen on their surface. Binding and fusion, reverse transcription, integration, transcription, assembly and budding are the major steps of the HIV life cycle. The HIV/AIDS disease is treated by interrupting the HIV life cycle with specially designed drugs. The discovery of effective drugs against HIV has focused on targeting various critical components of the replication cycle of HIV. Depending on the target within the HIV replicative cycle they interact with, anti-HIV compounds are categorized into six groups. These are: nucleoside (nucleotide) reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), cell entry inhibitors or fusion inhibitors (FIs), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The development of effective anti-HIV drugs is difficult due to wide variations in nucleotide and amino acid sequences. The development of anti-HIV drug passes through several important steps. This includes development from α-APA to ITU, ITU to DATA, DAPY to etravirine. Fosdevirine, lersivirine and rilpivirine are among the drugs that were undergoing clinical development and finally only rilpivirine was approved by FDA. The synthesis of delavirdine employs the use of heterocyclic rings like substituted pyridine and indole.

Synthesis of a New Anti-aids Drug Delavirdine Mesylate

Anti-HIV Drug Discovery, Development and Synthesis of Delavirdine: Review Article

Synthesis and Anti-Hiv Activity Evaluation of 2-(5-(naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-n-acetamides Derivatives

9-Hydroxymethylcyclopropylidenemethylenyladenine: The design, facile synthesis, isomer separation and anti-HIV-1 activities

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Synthesis and Anti-Hiv Activity Evaluation of 1-[(Alkenyl or Alkynyl or Alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

Anti-AIDS Agents 86. Synthesis and Anti-Hiv Evaluation of 2′,3′-Seco-3′-nor DCP and DCK Analogues

Synthesis and Biological Evaluation of 4-(Hydroxyimino)arylmethyl Diarylpyrimidine Analogues As Potential Non-Nucleoside Reverse Transcriptase Inhibitors Against HIV

New nordihydroguaiaretic acid derivatives as anti-HIV agents

Synthesis and spectroscopic analysis of 2′,3′-didehydro- 2′,3′-dideoxythymidine (d4T) 5′-thiophosphoramidates

Synthesis and Anti-Hiv Activity of Aryl-2-[(4-Cyanophenyl)Amino]-4-Pyrimidinone Hydrazones As Potent Non-Nucleoside Reverse Transcriptase Inhibitors

Synthesis and Spectroscopic Analysis of 2′,3′-O-Ethoxymethylidene Adenosine 5′-Thiophosphoramidates

Synthesis and Biological Evaluation of New Conformationally Restricted S-DABO Hybrids As Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

Synthesis of Novel Dimeric Steroidal-nucleoside Phosphoramidates

A new synthesis of the amine fragment: an important intermediate to the anti-HIV drug lenacapavir

Synthesis of aromatic-linked polyamine macrocyclic derivatives as HIV-1 entry inhibitors

Synthesis of Favipiravir

Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.

Anti-AIDS Agents 82: Synthesis of Seco-(3′R,4′r)-3′,4′-di-o-(s)-camphanoyl-(+)-cis-khellactone (DCK) Derivatives As Novel Anti-Hiv Agents

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors